Bristol Myers Squibb clinches acquisition of Forbius
Adds phase 1 isoform-selective TGF-beta inhibitor AVID200 to pipeline
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
immunotherapy
Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program
Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…
Bristol Myers Squibb to acquire Forbius
Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in Phase 1 for oncology and fibrosis
Researchers develop technology to see inside cells
The new technology may help answer outstanding questions about the immune system, cancer, Alzheimer’s, and more
Cancer CART therapy: What are the benefits and stakes?
Debamita Chatterjee, Ex-researcher, Harvard Medical School and NYAS/MIT/European Commission Innovation Mentor elaborates how…
Study reveals immunotherapy after chemotherapy slows metastatic bladder cancer
The randomised Phase 2 trial tested this treatment in 108 patients. The results of the clinical trial led by Mount Sinai…
Virtual Bio Pharma Conclave 2020 – Accelerating Biopharma Innovation | 21st April 2020
Recent Advancement In Cancer Immunotherapy And Novel CAR-T Development ~ Tue, Apr 21, 2020 | 3:00 PM - 4:00 PM IST
Roche’s Atezolizumab receives DCGI approval for small cell lung cancer treatment in India
Atezolizumab is the first cancer immunotherapy to receive an approval in India for the first line treatment of ES-SCLC when given…
Researchers develop effective nano-vaccine for melanoma
The focus of the research, published in the journal Nature Nanotechnology, is on a nanoparticle that serves as the basis for the…